The Conversation (0)
Biocure Technology Inc. (CSE:CURE, OTCQB:BICTF) (the “Company” or “Biocure”) BiocurePharm, Korea (“BPK”), a wholly owned subsidiary of Biocure Technology Inc. (“CURE”) has entered into a collaboration agreement with Y Biologics (“YB”), a private R&D company in Korea who is specialized in antibody therapeutics in cancer, autoimmune disease and metabolic disease.
Biocure Technology Inc. (CSE:CURE, OTCQB:BICTF) (the “Company” or “Biocure”) BiocurePharm, Korea (“BPK”), a wholly owned subsidiary of Biocure Technology Inc. (“CURE”) has entered into a collaboration agreement with Y Biologics (“YB”), a private R&D company in Korea who is specialized in antibody therapeutics in cancer, autoimmune disease and metabolic disease. The purpose of this agreement is to research the effectiveness of combined treatment of Immune Checkpoint Inhibitor PD-1 (Programmed Cell Death Protein-1) developed by YB and anti-CD19 CAR T-Cell Therapy developed by BPK. BPK and YB believe that the above combined treatment could maximize anticancer effects and eventually develop a next generation anticancer treatment for solid tumors.
BPK and YB agreed to collaborate in the following areas to verify combined therapy of YBL-006 and anti-CD19 CAR T-cell therapy;
- Plan and implement pre-clinical trial(animal) for combined therapy
- Conduct a study of action mechanism and bio marker of combined therapy
- Development of anticancer treatment and exchange of information
- And other essential items to fulfill the intended goal of the agreement
Dr. Sang Mok Lee, CEO & President of CURE explains “I am excited to see BPK collaborate with Y Biologics to take the first step to move forward to develop a next generation anticancer treatment for solid tumors. CURE will be able to commercialize a blood cancer immune therapy using CAR T Cell Therapy within 2 years and it is our ultimate goal to treat solid tumors with CAR T Cell Therapy. I believe that a successful outcome from this collaboration could bring CURE an opportunity to present epoch-marking anticancer therapy for solid tumors to life-threatening patients. This might be one of our most powerful pipeline products to give the significant returns to our loyal shareholders who have been supporting us for many years.”
Y Biologics is a Korean private R&D Company specialized in antibody therapeutics in cancer, autoimmune disease and metabolic disease. It has three platform technologies to accelerate development of antibody therapeutics – Human antibody library, Receptor library and mammalian transient expression. Y Biologics has a plan to enter into a preclinical trial for YBL-006 imminently.
About Biocure
Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre- clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (“MS”) Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, a hair growth production product and a breast cancer detection kit.
ON BEHALF OF THE BOARD OF DIRECTORS
/S/ “SANG MOK LEE”
CEO and Director
For further information, please contact:
Biocure Technology Inc. Telephone: 604-609-7146, or
Rebecca Greco
Investor Relations
(416) 822-6483
Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.
Source: www.newsfilecorp.com